Open AccessThe Preliminary Study for Postoperative Radiotherapy Survival Associated with RUNX3 and TLR9 Expression in Lung Cancer
Author(s) -
Caixia Gao,
Tiankui Qiao,
Shengtao Yuan,
Xibing Zhuang
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.024
H-Index - 40
ISSN - 1179-1322
DOI - 10.2147/cmar.s305452
Subject(s) - lung cancer , tlr9 , cancer research , cancer , medicine , radiation therapy , radiosensitivity , tumor progression , signal transduction , cell cycle , oncology , immunology , biology , dna methylation , gene expression , biochemistry , gene
Many studies have reported that the inflammatory immune response related to TLR9 signaling activation participates in tumor development and affects the treatment outcome. RUNX3 functions as a tumor suppressor by regulating DNA methylation. RUNX3 protein plays an important role in TGF-β signaling pathway that is involved in tumor growth inhibition and apoptosis. At present, radiotherapy is still an important treatment in lung cancer, which induces immune response and affects the therapeutic outcome. The role of TLR9 signaling activation and RUNX3 in this process is not clear.